Cargando…
Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
The increase in obesity and the aging of the population has lead to an increase in the incidence of type 2 diabetes. This has led to the development of new drugs such as thiazolidinediones (TZDs) which are Peroxisome Proliferator-Activated Receptor (PPARgamma) agonists, to treat type 2 diabetes. TZD...
Autores principales: | Desouza, Cyrus V., Shivaswamy, Vijay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411525/ https://www.ncbi.nlm.nih.gov/pubmed/22879786 |
Ejemplares similares
-
PSUN188 Evaluating Response to GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Managed at a Veterans Affairs Hospital
por: Davis, Clifton, et al.
Publicado: (2022) -
A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes
por: Dorkhan, Mozhgan, et al.
Publicado: (2007) -
Risk management in the treatment of type 2 diabetes with pioglitazone
por: Derosa, Giuseppe, et al.
Publicado: (2009) -
Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review
por: Kedia, Rohit, et al.
Publicado: (2016) -
SAT-516 A Retrospective Review of Osteoporosis Diagnosis and Management at a VA Hospital
por: Purushothaman, Archana, et al.
Publicado: (2019)